GlassScriptPhysician profile
Wajdi A Dbouk
NPI 1023073764
$7,992.42
in general payments reported to CMS, 2019-2025
35 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $1,222 · 2021: $1,650 · 2022: $1,332 · 2023: $1,267 · 2024: $917 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,047.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,025.53 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $797.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $505.10 | 2019-2024 | |
| Lilly USA, LLC | $495.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $491.87 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $429.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.60 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $354.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $341.89 | 2019-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.68 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Pfizer INC. | $272.61 | 2019-2025 | |
| Abbvie INC. | $221.02 | 2019-2025 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $165.48 | 2019-2021 | |
| Abbott Laboratories | $131.08 | 2020-2024 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $127.16 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $122.06 | 2019-2021 | |
| Vbi Vaccine (Delaware) INC. | $82.01 | 2023 | Prehevbrio |
| Nevro Corp. | $80.04 | 2023-2024 | Senza |
| Sk Life Science, INC. | $72.13 | 2021 | |
| Astellas Pharma US INC | $68.56 | 2020-2024 | Veozah |
| Boston Scientific Corporation | $68.21 | 2023 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $58.73 | 2021-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $53.79 | 2020 | |
| Phathom Pharmaceuticals, INC. | $53.56 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $40.09 | 2024 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $39.70 | 2020-2022 | |
| Insmed, INC. | $37.68 | 2021 | |
| Esperion Therapeutics, INC. | $31.63 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $29.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.04 | 2021 | |
| Shield Therapeutics INC | $16.55 | 2024 | |
| Viatris Specialty LLC | $14.11 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2019 | |
| Daiichi Sankyo INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wajdi Dbouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.